Press Release

- Management to hold conference call at 10:00 a.m. EST -

JERUSALEM--(BUSINESS WIRE)--Nov. 3, 2014-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited financial results for the quarter ended September 30, 2014 on Monday, November 10, 2014, before the U.S. markets open.

The Company will host a conference call on Monday, November 10 at 10:00 a.m. EST, featuring remarks by Kinneret Savitsky, Ph.D., Chief Executive Officer of BioLineRx, and Philip Serlin, Chief Financial and Operating Officer of BioLineRx.

The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx’s website, www.biolinerx.com. A presentation will be provided on BioLineRx’s website, to accompany management’s remarks during the conference call. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. To dial into the conference call, please dial 1-866-229-7198 from the U.S. or +972-3-918-0685 internationally.

A replay of the conference call will be available approximately two hours after completion of the live conference call at www.biolinerx.com. A dial-in replay of the call will also be available until November 13, 2014. To access the replay, please dial 1-888-295-2634 from the U.S. or +972-3-925-5937 internationally.

About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx’s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a pivotal CE-Mark registration trial scheduled for completion in mid-2015; BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for acute myeloid leukemia (AML) as well as a Phase 1 study for stem cell mobilization; and BL-7010 for celiac disease, which is in the final stages of a Phase 1/2 study.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases, and events. BioLineRx’s IR app is available on the iTunes App Store as well as the Google Play Store.

Source: BioLineRx Ltd.

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
+1-212-375-2664
jdrumm@tiberend.com
or
Andrew Mielach
+1-212-375-2694
amielach@tiberend.com
or
Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipihai5@gmail.com